What is NADMED?
NADMED Ltd is a specialized biotechnology firm focused on developing and providing advanced measuring kits and laboratory services for nicotinamide adenine dinucleotide (NAD) levels. The company serves clinical laboratories and research institutions with its CE-marked blood and RUO tissue/cell kits, enabling accurate and rapid quantification of NAD and glutathione. Originating from research at the University of Helsinki, NADMED's mission is to empower healthcare providers with precise diagnostic tools to personalize therapies for metabolic and degenerative diseases, thereby enhancing clinical care through scientific innovation.
How much funding has NADMED raised?
NADMED has raised a total of $3.8M across 1 funding round:
Series A
$3.8M
Series A (2024): $3.8M with participation from Nordic Science Investments Oy
Key Investors in NADMED
Nordic Science Investments Oy
Nordic Science Investments (NSI) is a venture capital firm that partners with founders to commercialize scientific discoveries, with a focus on deeptech, healthtech, and life sciences. They invest in science-based startups and provide incubation support to help transform innovations into impactful companies.
What's next for NADMED?
The recent major strategic investment positions NADMED for significant expansion and further development of its diagnostic solutions. This capital infusion is expected to accelerate the company's growth trajectory, enabling enhanced research and development, broader market penetration, and the scaling of its laboratory services. NADMED's focus on the critical role of NAD levels in health and disease suggests a strategic push towards becoming a leader in personalized medicine diagnostics.
See full NADMED company page
